Anakinra biosimilar (Hamad Medical Corporation)

阿那白滞素生物类似药（Hamad Medical Corporation）

Report date: 2026/04/30 20:00:20

Base Information

Drug NameAnakinra biosimilar (Hamad Medical Corporation)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterleukin-1 receptor antagonists
TargetsInterleukin-1 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeCoronavirus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryQatar
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHamad Medical Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHamad Medical Corporation
Active IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeVirus Diseases +[4] 
Inactive IndicationsCoronavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A